Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | RPA1 | P27694 | 1/20 | 0.55 |
| ▸ | MALT1 | Q9UDY8 | 11/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MARS1 | P56192 | 4/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30513027 | 1.00 | CNR1 (0.59) | CNR1RPA1MALT1MEN1LMNA | |
| SCHEMBL24209030 | 1.00 | CNR1 (0.59) | CNR1RPA1MALT1MEN1LMNA | |
| SCHEMBL24209029 | 0.88 | CNR1 (0.50) | CNR1RPA1MALT1MEN1LMNA | |
| SCHEMBL8742182 | 0.86 | CNR1 (0.62) | CNR1RPA1MALT1MEN1LMNA | |
| SCHEMBL24209055 | 0.84 | MALT1 (0.54) | MALT1MARS1NFKB1NFKB2RELA | |
| SCHEMBL25211931 | 0.84 | MALT1 (0.54) | MALT1MARS1NFKB1NFKB2RELA | |
| SCHEMBL24208665 | 0.84 | CNR1 (0.58) | CNR1 | |
| SCHEMBL30513100 | 0.84 | CNR1 (0.58) | CNR1 | |
| SCHEMBL24208703 | 0.84 | CNR1 (0.58) | CNR1 | |
| SCHEMBL24208783 | 0.82 | CNR1 (0.72) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | TIMP3, AFG3L2, MMP3 | CNR1 4650/4885RPA1 2809/4885MALT1 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.